Abstract
Purpose: Treatment of struvite kidney stones requires complete surgical stone removal combined with antibiotic therapy to eliminate urinary tract infections and preventive measures to reduce stone recurrence. The optimal duration of antibiotic therapy is unknown. We sought to determine if 2- or 12-weeks of antibiotics post percutaneous nephrolithotomy (PNL) for infection stones resulted in better outcomes for stone recurrence and positive urine cultures. Material and methods: This multi-center, prospective randomized trial evaluated patients with the clinical diagnosis of infection stones. Patients were randomized to 2- or 12-weeks of postoperative oral antibiotics (nitrofurantoin or culture-specific antibiotic) and included if residual fragments were ≤4 mm on computed tomography imaging after PNL. Imaging and urine analyses were performed at 3-, 6-, and 12-months post-procedure. Results: Thirty-eight patients were enrolled and randomized to either 2-weeks (n = 20) or 12-weeks (n = 18) of antibiotic therapy post-PNL. Eleven patients were excluded due to residual fragments >4 mm, and 3 patients were lost to follow-up. The primary outcome was the stone-free rate (SFR) at 6 months post-PNL. At 3-, 6-, and 12-months follow-up, SFRs were 72.7% versus 80.0%, 70.0% versus 57.1%, 80.0% versus 57.1% (p = ns), between 2- and 12-week-groups, respectively. At 3-, 6-, and 12-months follow-up, positive urine cultures were 50.0% versus 37.5%, 50.0% versus 83.3%, and 37.5% versus 100% between 2- and 12-week groups, respectively (p = ns). Conclusions: For patients with stone removal following PNL, neither 2-weeks nor 12-weeks of postoperative oral antibiotics is superior to prevent stones and recurrent positive urine cultures.
Original language | English (US) |
---|---|
Pages (from-to) | 1551-1558 |
Number of pages | 8 |
Journal | International Journal of Urology |
Volume | 29 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2022 |
Funding
Ben H. Chew is a consultant, teacher, speaker, or clinical trial PI for Boston Scientific, Olympus, The Ureteral Stent Company, AdvaTec, and Sonomotion. Alina Reicherz (RE 4611/2–1) is funded by the German Research Foundation (DFG). The funding source had no role in the design, practice, or analysis of this study. Amy E. Krambeck is a consultant for Virtuoso, BSC, Lumenis, Storz, and Ambu and a DSMB member of Upiprene, Sonimotion, and NIH. The funding source had no role in the design, practice, or analysis of this study. Nicole L. Miller is a consultant for Virtuoso surgical, Boston Scientific, Intuitive Surgical, and Becton Dickinson and was supported by research grant from Karl Storz Endoscopy. The funding source had no role in the design, practice, or analysis of this study. Ryan S.His, Kymora B. Scotland, David Miller, Ryan F. Paterson, and Victor K.F. Wong declare no conflict of interest. Michelle J. Semins is a consultant for Cook and Boston scientific and a PI for UPMC site for a study with Applaud Medical. The funding source had no role in the design, practice, or analysis of this study. Dirk Lange is a consultant, speaker, and study PI for Boston Scientific and Scientific Advisor for Kisolite.
Keywords
- PNL
- antibiosis
- infection stones
- nephrolithiasis
- struvite
ASJC Scopus subject areas
- Urology